Literature DB >> 21810292

Transcatheter arterial embolisation for paediatric inflammatory pseudotumour of the maxillary sinus.

A Murai1, K Sugiu, S Kariya, K Nishizaki.   

Abstract

BACKGROUND: Inflammatory pseudotumours are mostly seen in the lung, and occasionally in the head and neck region including the sinonasal area. Reported treatment modalities comprise corticosteroid treatment, surgical excision and radiotherapy. The latter option is required because wide surgical resection may be difficult for head and neck lesions, especially in children. However, clinicians should be aware of the risk of late-onset side effects of radiotherapy in children. CASE REPORT: We present a two-year-old girl with a massive inflammatory pseudotumour of the maxillary sinus. Transcatheter arterial embolisation was performed, and the lesion was successfully managed without additional therapy. There was no evidence of recurrence over the next five years.
CONCLUSION: This is the first report presenting the utility of arterial embolisation for inflammatory pseudotumour.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21810292     DOI: 10.1017/S0022215111001848

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  3 in total

1.  An Inflammatory Pseudotumor Arising from Pterygopalatine Fossa with Invasion to the Maxillary Sinus and Orbital Cavity.

Authors:  Hidenori Yokoi; Takuya Yazawa; Yuma Matsumoto; Tetsuya Ikeda; Masachika Fujiwara; Yasuo Ohkura; Naoyuki Kohno
Journal:  Case Rep Otolaryngol       Date:  2015-06-18

2.  Pulmonary inflammatory pseudotumor with jaundice and anemia: A case report.

Authors:  Avradip Santra; Abhishek Bandyopadhyay; Amitabha Sengupta; Saibal Mondal
Journal:  Lung India       Date:  2017 Mar-Apr

3.  Maxillary sinus inflammatory myofibroblastic tumors: a review and case report.

Authors:  Chase C Hansen; Colby Eisenbach; Carlos Torres; Suzanne Graham; Fred Hardwicke
Journal:  Case Rep Oncol Med       Date:  2015-02-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.